This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnosticradiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnosticimaging, hospital administrators may be eyeing the potential of adding theranostics services. Louis is unique for radiopharmaceutical therapy patient triage, Prasad said. Also be mindful of design requirements in the U.S.;
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
produced, non-uranium based Mo-99 for use in diagnosticimaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.
The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.
Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnosticimaging and theranostics appeared first on Open Medscience.
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.
Radiotheranostics combines diagnosticimaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.
Radiotheranostic treatments combine diagnosticimaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness. The post Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications appeared first on Open MedScience.
In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
An assistant professor of radiology and radiological science, Francis Deng, MD, is the Johns Hopkins radiology department's co-director of medical student diagnostic radiology electives. His area of expertise is neuroradiology, with a special emphasis on diagnosticimaging of the head, neck, brain, and spine. Elliot Fishman, MD.
Currently in phase III trials, the 64Cu-SAR-bisPSMA PET agent reportedly offers a longer half-life and higher tumor uptake than other radiopharmaceuticals for prostate cancer imaging.
Radiotheranostics offers a precise, personalised approach to cancer treatment by combining diagnosticimaging with targeted therapy The post The Future of Radiotheranostics: A New Frontier in Precision Medicine appeared first on Open MedScience.
shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnosticradiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Blue Earth Diagnostics received U.S.
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3
Precision PET imaging with POSLUMA can help identify the location and extent of prostate cancer, providing clinically valuable information to guide patient management. Blue Earth Diagnostics received U.S. Food and Drug Administration approval for its radiohybrid PET diagnosticimaging product for use in prostate cancer in 2023.
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnosticimaging, and radiopharmaceuticals.
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnosticimaging, and radiopharmaceuticals.
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nationwide equipment sales, service, parts, turnkey diagnosticimaging, and radiopharmaceuticals. Request a meeting with one of our Regional Sales Managers at sales@ttgimagingsolutions.com.
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnosticimaging, and radiopharmaceuticals.
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnosticimaging, and radiopharmaceuticals.
More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnosticimaging. Product life extension & upgrades GE HealthCare is also proud to offer global refurbished medical equipment, helping to improve access to affordable, quality healthcare.
Discuss how these advancements enhance imaging capabilities, providing clearer insights into physiological processes. Discuss how theranostic approaches integrate diagnosticimaging and targeted therapy for more personalized and effective treatments.
Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad DiagnosticImaging, Inc and Digirad Imaging Solution, Inc.
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad DiagnosticImaging, Inc and Digirad Imaging Solution, Inc.
Discuss how PET/CT and PET/MRI combinations offer superior imaging capabilities, providing both anatomical and functional information in a single examination. Advancements in Radiopharmaceuticals: Precision Imaging Agents: Discuss the latest developments in radiopharmaceuticals.
Radiotheranostic Pairs combine diagnosticimaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.
Cancer radiotheranostics combines targeted radiotherapy and diagnosticimaging to provide personalised, precise, and effective cancer treatment. The post Cancer Radiotheranostics: The Future of Targeted Cancer Therapy appeared first on Open MedScience.
The organization brought a robust customer base in the mid-west along with a strong group of field service engineers The following executive leadership changes are effective November 1, 2021: Jack Tomayko, Ph.D., Remaining in their current roles are John Nalley, EVP of Equipment Service Operations, and Hunter Forestier, VP of Sales and Marketing.
Nuclear Medicine and Theranostics : Nuclear medicine radiologists specialize in advanced imaging techniques, such as PET/CT scans, to detect and treat conditions at the molecular level. They also lead the field in theranostics , which combines diagnostics and therapy in one procedure.
A dedicated teacher and radiologic technologist since 2009, Stewart currently serves as associate professor of diagnosticimaging, and program director of radiologic sciences at Quinnipiac University in Connecticut. from Ukraine.
Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.” PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging, ” by Phillip H.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content